Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Compass Pathways announced its third quarter 2026 financial results, highlighting significant progress in mental health treatments. The company emphasized its commitment to developing COMP360, a treatment aimed at individuals with treatment-resistant depression (TRD). This initiative is part of a broader effort to provide new options for mental health care.

Market Sentiment Analysis

POSITIVE FACTORS

  • Reported strong financial results for Q3 2026.
  • COMP360 shows promise for treating TRD.
  • Company is focused on mental health advancements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+172%
120-day peak, hindsight
Typical move
8.6%
average across 3 past catalysts
Cash runway
~29 mo
Low dilution risk
Lead asset
COMP360
Phase 3 · Treatment Resistant Depression

Full Press Release Details

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results and business highlights. "Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 ha

Frequently Asked Questions

What did Compass Pathways report for Q3 2026?

Compass Pathways reported strong financial results and business highlights.

What is COMP360?

COMP360 is a treatment aimed at individuals with treatment-resistant depression.

Why is Compass Pathways significant in mental health care?

The company is focused on developing new treatment options for mental health.

Where is Compass Pathways based?

Compass Pathways is based in London and Jersey City, N.J.

ShareAdd on Google
Tags: CMPS Compass Pathways mental health COMP360 treatment-resistant depression
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$433M liquidity · $13M/mo burn
~29 mo
Low dilution risk
Lead asset
COMP360Phase 3
Treatment Resistant Depression →

Catalyst track record

+172%
best trade around CMPS's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CMPS.

See every catalyst's timing & PoA →